A detailed history of Fox Run Management, L.L.C. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 45,650 shares of CPRX stock, worth $986,953. This represents 0.21% of its overall portfolio holdings.

Number of Shares
45,650
Holding current value
$986,953
% of portfolio
0.21%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$15.19 - $21.35 $693,423 - $974,627
45,650 New
45,650 $907,000
Q1 2024

May 13, 2024

BUY
$13.18 - $17.11 $367,102 - $476,564
27,853 New
27,853 $443,000
Q3 2023

Nov 07, 2023

BUY
$11.69 - $15.02 $396,022 - $508,832
33,877 New
33,877 $396,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.22B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.